Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SPECTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SPECTAMINE.
MPI DMSA KIDNEY REAGENT vs SPECTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
SPECTAMINE (iofetamine I-123) is a radiopharmaceutical that crosses the blood-brain barrier and localizes in the brain proportional to regional cerebral blood flow. It binds to striatal dopamine transporters (DAT) and is used as a marker for dopamine transporter density.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
SPECTAMINE (technetium Tc-99m exametazime) is administered intravenously. For brain imaging, the recommended adult dose is 10-20 mCi (370-740 MBq). For white blood cell labeling, the dose is 10-20 mCi (370-740 MBq) after labeling autologous leukocytes.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal elimination half-life: 13-17 hours; clinically, effective half-life for brain SPECT imaging is 6-9 hours due to redistribution.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: >90% as unchanged drug within 24 hours; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical